Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1703 • ACR Convergence 2024
Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Rachael Wasikowski¹, Erin Theisen², Jie An³, Lam C. Tsoi¹, Ksenia Anufrieva⁴, Kevin Wei⁵, Johann Gudjonsson⁶ and Keith Elkon³, ¹Michigan, Dept. of Dermatology, Ann Arbor, MI, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Washington, Seattle, WA, ⁴BWH, Cambridge, MA, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
Abstract Number: 1785 • ACR Convergence 2024
Comparative Immuno-Metabolomics Shows Singular Changes in Systemic Lupus Erythematosus Metabolic Phenotype Induced by T-Cell Activation
Martin Stradner¹, Fernanda Monedeiro², Elmar Zuegner², Barbara Prietl³, Monika Oberhuber⁴, Michael Khalil⁵, Christoph Magnes², Hans-Peter Brezinsek¹, Angela Libiseller³ and Thomas Pieber³, ¹Div. of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ²Joanneum Research, Graz, Austria, ³Div. of Endocrinology, Medical University of Graz, Graz, Austria, ⁴CBmed, Graz, Austria, ⁵Dept. of Neurology, Medical University of Graz, Graz, Austria
Background/Purpose: Metabolic processes have a critical role in regulating immune cell function, therefore being relevant to understanding the pathogenesis and progression of autoimmune diseases. Here…
Abstract Number: 1804 • ACR Convergence 2024
Investigating Adaptive Immune Receptor Repertoires by Deep Immune Cell Phenotyping in Preclinical Autoimmunity Development
Aleksandra Bylinska¹, Miles Smith¹, Rufei Lu¹, Benjamin Jones², Carla Guthridge¹, Matthew Caleb Marlin¹, Christian Wright³, Susan Macwana³, Wade DeJager³, Marci Beel³, Christopher Lessard¹, Cristina Arriens¹, Joan Merrill⁴, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma State University, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: A loss of systemic self-tolerance to anti-nuclear autoantibodies (ANAs) is one of the main hallmarks of SLE. However, most healthy females with ANAs will…
Abstract Number: 1933 • ACR Convergence 2024
Telemedicine for Under-resourced Patients with Systemic Lupus Erythematosus: A Qualitative Study Exploring the Views and Experiences of Patients and Rheumatology Health Care Professionals
Sebastian Bruera¹, Savannah Bowman¹, Keshia Ferguson¹, MaryJo Maliekel¹, Maria A. Lopez-Olivo², Maria Suarez-Almazor³, Maria I. ("Maio") Danila⁴, Jinoos Yazdany⁵ and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³MD Anderson Cancer Center, Houston, TX, ⁴University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ⁵UCSF, San Francisco, CA
Background/Purpose: There is a paucity of knowledge regarding the benefits and limitations of telemedicine in patients with SLE, particularly in those with under-resourced backgrounds. We…
Abstract Number: 2370 • ACR Convergence 2024
Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
Daniella Faden¹, lillian Xie², Caroline Stone¹, Lais Lopes Almeida Gomes¹, Ahmed Eldaboush¹, Cristina Ricco², Rui Feng² and Victoria Werth³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Regulatory guidance on endpoint measures for disease activity in cutaneous lupus erythematosus (CLE) patients is essential to improve therapies. CLE profoundly impacts quality of…
Abstract Number: 2387 • ACR Convergence 2024
Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
Madeline Alizadeh¹, Vishnuprabu Pandian¹, Christele Felix², Andrra Nimoni², Jasmin Divers³, Timothy Niewold² and Ashira Blazer¹, ¹University of Maryland Baltimore, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Compared to Apolipoprotein L1 (APOL1) low risk genotype (LRG) patients, APOL1 (HRG) has been shown to increase the risk of chronic kidney disease in…
Abstract Number: 2407 • ACR Convergence 2024
Clinical Utility of Repeat Renal Biopsies in Lupus Nephritis: The NIH Chronicity Index at First Biopsy Predicts Future End Stage Renal Disease in a Large South Asian Cohort of SLE
Rudrarpan Chatterjee¹, Neeraja Vijayan², Durga P Misra³, Vikas Agarwal³, Able Lawrence⁴ and Amita Aggarwal⁵, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow., Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁴SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Renal biopsy remains a cornerstone of management of lupus nephritis. Repeat renal biopsies after therapy help prognosticate renal outcomes. We sought to describe the…
Abstract Number: 2423 • ACR Convergence 2024
Associations Between Cytometric Interferon Signature and Clinical Response in a Cohort of Anifrolumab-treated Patients with Lupus
Alice Horisberger¹, Katharina Shaw², Eilish Dillon³, Kathryne Marks⁴, Rochelle Castillo⁵, Ifeoluwakiisi Adejorin⁶, Kimberly Hashemi⁴, Karen Costenbader⁷, Avery LaChance⁸, Ruth Ann Vleugels⁵ and Deepak Rao¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Perelman School of Medicine at the University of Pennsylvania, Merion Station, PA, ³University of Massachusetts Boston, Yarmouth, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁸Brigham and Women's Hospital, Jamaica Plain, MA
Background/Purpose: Anifrolumab, a monoclonal antibody targeting type I interferon (IFN-I) receptor subunit 1, was recently approved for the treatment of systemic lupus erythematosus (SLE) and…
Abstract Number: 2440 • ACR Convergence 2024
Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics
Irene Carrión-Barberà¹, Tarek Carlos Salman Monte:², Laura Triginer³, María García-Villanueva⁴, Sandra Garrote Corral⁵, Anne Riveros Frutos⁶, Judit Font⁷, María Galindo-Izquierdo⁸, Carlos de Frías Polo⁹, Jorge Juan Fragío Gil¹⁰, Clara Moriano¹¹, Elvira Díez Álvarez¹², Pilar Bernabéu¹³, Paloma Vela-Casasempere¹⁴, Josefina Cortés-Hernández¹⁵, Sebastián Sandoval Moreno¹⁶, Javier Narvaez-García¹⁷, Andrea Hernández-Martín¹⁸, Berta Paula Magallares¹⁹, María Piqueras García²⁰, Carlos Marras²¹, Consuelo Ramos²², Jose Alfredo Gomez-Puerta²³, Beatriz Frade-Sosa²⁴, Ana Fernández-Ortiz²⁵, Angel Garcia-Aparicio²⁶, Irene Altabás-González²⁷, Samuel Hernández-Baldizón²⁸, Inmaculada Ros-Vilamajó²⁹, Silvia García Cirera³⁰, Marta Garijo Bufort³¹, Luis Sala³², Julia Martínez-Barrio³³, José Rosas-Gómez de Salazar³⁴, Sergi Heredia³⁵, Vicenç Torrente-Segarra³⁶, Anahy Maria Brandy-Garcia³⁷, Natividad del Val del amo³⁸, Concepción Fito-Manteca³⁸, Jaime Calvo-Alen³⁹, José María Pego-Reigosa⁴⁰ and Íñigo Rúa-Figueroa⁴¹, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³Hospital del Mar Research Institute, Barcelona, Spain, ⁴Hospital Ramón y Cajal, MADRID, Madrid, Spain, ⁵Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ⁸Hospital 12 de Octubre, Madrid, Madrid, Spain, ⁹Hospital 12 de Octubre, Madrid, Spain, ¹⁰Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital León, LEON, Spain, ¹²Complejo Asistencial Universitario de León, León, Spain, ¹³Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ¹⁴Hospital General Universitario Alicante, Alicante, Spain, ¹⁵Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ¹⁶Hospital Vall d'Hebron, Barcelona, Spain, ¹⁷Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, ¹⁹Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain, ²⁰Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ²²Hospital Universitario Virgen de Valme, Sevilla, Spain, ²³Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²⁴Hospital Clínic, Barcelona, Spain, ²⁵Hospital Universitario de Badajoz, Badajoz, Spain, ²⁶Hospital Universitario de Toledo, Toledo, Spain, ²⁷Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ²⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ³⁰Hospital Parc Taulí, Sabadell, Spain, ³¹Hospital de Sagunto, Sagunto, Spain, ³²Hospital Universitario de Torrejón, Torrejón, Spain, ³³Hospital Gregorio Marañón, Madrid, Spain, ³⁴Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ³⁵Hospital Moisès Broggi, Sant Joan Despí, Spain, ³⁶Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³⁷Hospital Germans Trias i Pujol, Badalona, Spain, ³⁸Complejo Universitario de Navarra, Navarra, Spain, ³⁹Hospital Universitario de Araba, Araba, Spain, ⁴⁰Galicia Health Service (SERGAS), Vigo, Spain, ⁴¹Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain
Background/Purpose: Anifrolumab is a biological treatment with recent approval for systemic lupus erythematosus (SLE), supported by its efficacy in clinical trials. However, data from real…
Abstract Number: 2603 • ACR Convergence 2024
A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation
Gregg Silverman¹ and Laurence Morel², ¹NYU Grossman School of Medicine, New York, NY, ²Joe R. & Teresa Lozano Long School of Medicine, San Antonio, TX
Background/Purpose: The mechanisms by which the gut microbiome contributes to autoimmune pathogenesis remain poorly understood. In lupus patients, more than ten-fold blooms of Ruminococcus gnavus…
Abstract Number: PP14 • ACR Convergence 2024
Support Groups and Chronic Illness: Finding Social Support Among Peers
Alexandra Blumhorst¹ and Estela Mata-Carcamo², ¹Looms for Lupus, Silver Spring, MD, ²Looms for Lupus, Irwindale, CA
Background/Purpose: Like many lupus patients, my journey has been long, complex, and difficult. I began experiencing symptoms in 2019. Over the next five years, I…
Abstract Number: 0092 • ACR Convergence 2024
A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Hulya Bukulmez¹, Adrienne Dennis², kristine Highland³ and Steven N. Emancipator⁴, ¹MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, ²MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH
Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
Abstract Number: 0167 • ACR Convergence 2024
Epidemiology of Falls in a Diverse Cohort of Adults with SLE
Laura Plantinga¹, Charmayne M. Dunlop-Thomas², Courtney Hoge³, Jinoos Yazdany⁴ and C. Barrett Bowling⁵, ¹University of California, San Francisco, San Francisco, CA, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴UCSF, San Francisco, CA, ⁵Duke University, Durham, NC
Background/Purpose: While often preventable, falls are a common, costly, and serious outcome in the U.S. population: more than one in four adults ³65 years old…
Abstract Number: 0191 • ACR Convergence 2024
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
Alyssa Howren¹, Quan Le Tran¹, Sadaf Sediqi¹, Saadiya Hawa², Eleni Linos¹, Titilola Falasinnu³, Yashaar Chaichian¹ and Julia Simard¹, ¹Stanford School of Medicine, Stanford, CA, ²Weiss Memorial Hospital, Chicago, IL, ³Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune rheumatic disease whose prognosis varies by race and sex. To understand whether the cognitive processes of…
Abstract Number: 0353 • ACR Convergence 2024
Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Joy Buie¹, Michael Fisher¹, Hannah Tlydsley², Kristen Backor² and Karen Costenbader³, ¹Lupus Foundation of America, Washington, DC, ²Charles River Associates, San Francisco, CA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Health disparities among racial and ethnic minoritized individuals living with lupus remain a critical public health concern. Challenges related to healthcare affordability, accessibility, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].